[HTML][HTML] Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European …
VD de Jager, W Timens, A Bayle, J Botling… - The Lancet Regional …, 2024 - thelancet.com
In the past two decades, the treatment of metastatic non-small cell lung cancer (NSCLC),
has undergone significant changes due to the introduction of targeted therapies and …
has undergone significant changes due to the introduction of targeted therapies and …
Frequency, underdiagnosis, and heterogeneity of epidermal growth factor receptor exon 20 insertion mutations using real‐world genomic datasets
S Viteri, A Minchom, L Bazhenova, SHI Ou… - Molecular …, 2023 - Wiley Online Library
Epidermal growth factor receptor (EGFR) exon 20 insertion mutations (ex20ins) account
for≤ 12% of all EGFR‐mutant nonsmall cell lung cancers. We analysed real‐world datasets …
for≤ 12% of all EGFR‐mutant nonsmall cell lung cancers. We analysed real‐world datasets …
[HTML][HTML] Mutation-tailored treatment selection in non-small cell lung cancer patients in daily clinical practice
EMP Steeghs, HJM Groen, E Schuuring, MJ Aarts… - Lung Cancer, 2022 - Elsevier
Objectives The number of targeted drugs in non-small cell lung cancer (NSCLC) is ever-
expanding and requires testing of an increasing number of predictive biomarkers. We …
expanding and requires testing of an increasing number of predictive biomarkers. We …
[HTML][HTML] Prevalence of KRAS p.(G12C) in stage IV NSCLC patients in the Netherlands; a nation-wide retrospective cohort study
BNC Garcia, LC van Kempen, CCHJ Kuijpers… - Lung Cancer, 2022 - Elsevier
Objectives The recent accelerated FDA approval of sotorasib, a highly selective KRAS G12C
inhibitor, offers new opportunities for the treatment of KRAS p.(G12C)-mutated non …
inhibitor, offers new opportunities for the treatment of KRAS p.(G12C)-mutated non …
[HTML][HTML] Prevalence, clinical and molecular characteristics of early stage EGFR-mutated lung cancer in a real-life West-European cohort: Implications for adjuvant …
LM Hondelink, SM Ernst, P Atmodimedjo… - European Journal of …, 2023 - Elsevier
Objectives The landmark ADAURA study recently demonstrated a significant disease-free
survival benefit of adjuvant osimertinib in patients with resected EGFR-mutated lung …
survival benefit of adjuvant osimertinib in patients with resected EGFR-mutated lung …
A real-world systematic analysis of driver mutations' prevalence in early-and advanced-stage NSCLC: implications for targeted therapies in the adjuvant setting
I Terrenato, C Ercolani, A Di Benedetto, E Gallo… - Cancers, 2022 - mdpi.com
Simple Summary The development of oncogene-targeted drugs has radically changed the
course of non small cell lung carcinoma (NSCLC) in the advanced stage. Recently, the …
course of non small cell lung carcinoma (NSCLC) in the advanced stage. Recently, the …
[HTML][HTML] A population-based study describing characteristics, survival and the effect of TKI treatment on patients with EGFR mutated stage IV NSCLC in the …
DMHJ Ten Berge, MJ Aarts, HJM Groen… - European Journal of …, 2022 - Elsevier
Introduction Since 2011, treatment guidelines advise targeted therapy (tyrosine kinase
inhibitor, TKI) for patients with activating epidermal growth factor receptor (EGFR) mutations …
inhibitor, TKI) for patients with activating epidermal growth factor receptor (EGFR) mutations …
[HTML][HTML] Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe
P Hofman, F Calabrese, I Kern, J Adam, A Alarcão… - ESMO open, 2023 - Elsevier
Background Testing for epidermal growth factor receptor (EGFR) mutations is an essential
recommendation in guidelines for metastatic non-squamous non-small-cell lung cancer, and …
recommendation in guidelines for metastatic non-squamous non-small-cell lung cancer, and …
Impact of time-to-treatment on survival for advanced non-small cell lung cancer patients in the Netherlands: a nationwide observational cohort study
SE Klarenbeek, MJ Aarts, MM van den Heuvel… - Thorax, 2023 - thorax.bmj.com
Background The assumption that more rapid treatment improves survival of advanced non-
small cell lung cancer (NSCLC) has not yet been proven. We studied the relation between …
small cell lung cancer (NSCLC) has not yet been proven. We studied the relation between …
Optimalisatie van de zorgketen moleculaire diagnostiek bij niet-kleincellig longcarcinoom in Noord-Nederland
VD de Jager, BNC Garcia, A ter Elst… - Nederlands Tijdschrift …, 2023 - research.rug.nl
Predictieve moleculaire diagnostiek speelt een belangrijke rol bij het bepalen van de
behandelmogelijkheden voor patiënten met (gemetastaseerd) niet-kleincellig …
behandelmogelijkheden voor patiënten met (gemetastaseerd) niet-kleincellig …